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Mammography screening may lead to overdiagnosis of asymptomatic breast cancers, that would otherwise not have given rise to
clinical symptoms. This aspect was studied in three regional screening programmes in Denmark, which started in Copenhagen
municipality, Fyn county, and Frederiksberg municipality in 1991, 1993, and 1994, respectively. In these regions, we compared time
trends in incidence of invasive breast cancer with the rest of Denmark. Since the number of clinical mammograms was relatively low,
it was reasonable to assume that the breast cancer incidence outside the three screening regions represented the incidence of a
population with low-intensity opportunistic screening. In Copenhagen and Fyn, a prevalence peak in incidence was seen during the
first invitation round. During the subsequent invitation rounds, the incidence dropped to a level in line with the incidence expected
without screening. The pattern was different in the small municipality of Frederiksberg, where the sensitivity was low during the first
invitation round. Inclusion of screen-detected ductal carcinoma in situ cases did not change these results. The experiences from
Copenhagen and Fyn show that organised mammography screening can operate without overdiagnosis of breast cancer.
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An overview of the five Swedish trials found that after 9 years
of follow-up, screening reduced breast cancer mortality by
29% in women aged 50–69 at the time of screening (Nystro ¨m
et al, 1993). Based on these results, mammography screening
has disseminated broadly both in organised programmes as in
the United Kingdom and the Netherlands, and as opportunistic
screening.
Mammography screening of asymptomatic women may also
have potential negative side effects such as overdiagnosis of
asymptomatic breast cancers that would otherwise not have
given rise to clinical symptoms. Overdiagnosis is difficult to study.
The introduction of screening will lead to a temporary increase
in the incidence of breast cancer as prevalent cases are picked
up by the screening. It may therefore be difficult to distinguish
between the expected ‘prevalence peak’ and an increase in
incidence derived from overdiagnosis. This is particularly the case
if screening is introduced gradually.
In Denmark, organised mammography screening is offered
to 50–69-year-old women every second year in only three out
of 16 administrative regions, and very little opportunistic
screening takes place in the remaining regions. Breast cancer
incidence can be monitored through the Danish Cancer Register.
Denmark is therefore a good ‘laboratory’ for studying the
effect of organised mammography screening on breast cancer
incidence. We report here on the incidence trends in the three
Danish mammography screening regions and in the rest of
Denmark.
MATERIALS AND METHODS
Screening programmes
The Copenhagen programme started on 1 April 1991 targeting all
40000 women aged 50–69 at the start of an invitation round. The
Fyn programme started in November 1993 targeting all 50000
women aged 50–69 on the day of invitation. The first invitation
round took place from November 1993 and 31 December 1995, but
the activity was low during the first 2 months, and subsequent
invitation rounds covered exactly 2 years starting from the 1st of
January. The Frederiksberg programme started in June 1994
covering 10000 women defined as in Copenhagen, and in 1996 was
incorporated into the Copenhagen programme. The three pro-
grammes together covered 100000 women, equivalent to 20% of
Danish women aged 50–69.
Mammograms
We distinguished between screening mammography offered in
the organised programmes to asymptomatic women, and clinical
mammography used for symptomatic women and sometimes
also for opportunistic screening of asymptomatic women. Our
counting unit is a mammographic examination, which will
normally include examination of both breasts, here termed a
mammogram.
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the database in the Copenhagen Hospital Organisation, covering
both Copenhagen and Frederiksberg (Mammography Screening
Evaluation Group, 1998), and from the health care database for
Fyn (Sundhedsstyrelsen, 1997).
The numbers of clinical mammograms performed in 1983–1987
were found in publications from the National Board of Health
(Sundhedsstyrelsen, 1989, 1995, 1997). For 1990–1991, data were
available from a survey in selected counties (Andreasen et al,
1994), and the total number for Denmark was estimated on this
basis. We estimated the proportion of clinical mammograms used
by women aged 50–69 from surveys conducted in 1984 (Pociot
et al, 1986) and 1990–1991 (Andreasen et al, 1994). For 2000,
individual records on clinical mammograms were collected
directly from all radiology centres.
Incidence of invasive breast cancer
The numbers of invasive breast cancers from 1985 to 1997 were
retrieved from the Danish Cancer Register, ICD-7 code 170
(International Classification of Diseases and Causes of Death 7th
edition), and behaviour code 3 (Sundhedsstyrelsen, 2001). To cal-
culate incidence rates, corresponding population data were
retrieved from Statistics Denmark (http://www.statistikbanken.dk).
Invasive breast cancers and population data were tabulated for
2-year periods for the target groups of the screening programmes.
For each of the three regions, similar populations were defined for
the periods before screening started, and for a comparison group
including the rest of Denmark except Copenhagen, Frederiksberg,
and Fyn. Cumulative rates were calculated by adding the age-
specific rates for women aged 50–54, 55–59, 60–64, and 65–69
years and multiplying by five. This was then converted to a
cumulative risk.
RESULTS
Numbers of mammograms
In total, 97000 mammograms were performed in Denmark in 2000:
38000 screening mammograms and 59000 clinical mammograms.
The number of screening mammograms has been stable over time
since the programmes started. The number of clinical mammo-
grams increased from about 36000 per year in 1983–1985, to
40000 in 1986, 45000 in 1987–1991, 48000 in 1995, and 59000 in
2000. The proportion of mammograms undertaken in women aged
50–69 was close to 30% in both 1984 and 1990–1991. This
percentage had, however, increased to 43% in 2000. By linear
interpolation we estimated the proportion to be 36% in 1995. The
estimated number of clinical mammograms performed in women
aged 50–69 thus increased from 10000 in 1983 to 25000 in 2000
(Figure 1).
Incidence of invasive breast cancer
Figure 2 shows the time trends in cumulative risk of invasive
breast cancer for women aged 50–69. There was a pronounced
prevalence peak during the first invitation round in Copenhagen,
after which the incidence dropped to the level in line with
the increasing incidence observed before screening started. The
pattern for Fyn was similar to that of Copenhagen for the
first invitation round with a pronounced prevalence peak, and
the incidence decreased during the second invitation rounds
but seemed a little higher than before screening started. The
picture for the small municipality of Frederiksberg was different,
as the incidence continued to be high during the second invitation
round. The incidence of breast cancer for the rest of Denmark
increased slightly during the years 1985–1997.
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Figure 1 Number of mammography examinations in Denmark in
women aged 50–69 during the years 1983–2000.
1985-87
1987-89
1989-91
1991-93
1993-95
1995-97 0
2
4
6
8
10
12
P
e
r
c
e
n
t
P
e
r
c
e
n
t
P
e
r
c
e
n
t
Copenhagen Rest of Denmark
1986-87
1988-89
1990-91
1992-93
1994-95
1996-97 0
2
4
6
8
10
12
Fyn Rest of Denmark
1986-88
1988-90
1990-92
1992-94
1994-96
1996-97 0
2
4
6
8
10
12
Frederiksberg Rest of Denmark
Prevalence 
round  Prevalence 
round 
Prevalence 
round
Figure 2 Cumulative risk (in per cent) of incident invasive breast cancer for women aged 50–69 in the three regions with organised mammography
screening and in Denmark excluding the screening regions. The pattern in Frederiksberg probably reflects low sensitivity during the first invitation round.
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Clinical mammography/opportunistic screening and
background incidence
Opportunistic screening has not been widespread in Denmark.
Even in 2000 only 59000 clinical mammograms were performed
in a population of 5.3 million compared with, for example,
220000 clinical mammograms in Norway in the mid-1990s in a
population of 4.5 million (Wang, 2002). In 2000, 25000 clinical
mammograms were undertaken in the 500000 women aged 50–69,
whereas there were 38000 screening mammograms in 100000 such
women in the three screening programmes.
It is, therefore, reasonable to assume that the incidence of
invasive breast cancer among women aged 50–69 in the rest of
Denmark during the period 1985–1997 represented the incidence
in a population with low-intensity opportunistic screening.
Incidence was quite stable at these ages from the start of the
Danish Cancer Register in 1943 until 1960, after which the
incidence increased by more than 50% to the mid-1980s
(Sundhedsstyrelsen, 2001). Our analysis showed that this increase
continued in the rest of Denmark in the late 1980s and 1990s.
Expected incidence of invasive breast cancers after the
start of screening
In a closed, nonageing population, the introduction of mammo-
graphy screening that detects early invasive cancers with a
100% sensitivity and with a 100% participation rate would be
expected to result in an increase in the incidence of invasive cancer
during the first invitation round, as prevalent asymptomatic
lesions are detected. When this population is rescreened at regular
intervals, incidence of invasive cancer is expected to drop to the
prescreening level, if the screening does not lead to overdiagnosis
of cases that would otherwise not have given rise to clinical
symptoms.
In an open, nonageing population with a screening programme
that detects early invasive cancers with a sensitivity below 100%,
with a participation rate below 100%, and offered biennially to
women aged 50–69, it is difficult to predict the level to which
incidence will drop after the first round, as there are forces
working in opposite directions. Any new invitation round will be a
prevalence round for newcomers to the programme, i.e. women
turning 50, women moving into the screening area, and previous
nonparticipants, and this will contribute to pushing the incidence
above the prescreening level. The lower sensitivity implies that
some prevalent cases will be left for detection at the second or
third screen. A certain proportion of screen-detected cases will also
be left for assessment and final diagnosis during the period of the
next invitation round. A decline in the participation rate over
invitation rounds will, on the other hand, tend to lower the
incidence.
If screening also detects ductal carcinoma in situ (DCIS) cases,
the incidence of invasive cancer is expected eventually to become
lower in the rescreening rounds than before screening. If there is
an underlying increase in the background risk of breast cancer,
these screening-induced changes in incidence will be added to the
background trend.
Observed incidence of invasive breast cancer after start of
screening
In both Copenhagen and Fyn, a prevalence peak was clearly shown,
followed by an incidence during subsequent rounds fairly similar
to that expected without screening. Compared to the prescreening
period, the incidence was roughly doubled in the prevalence round
in both regions. Given no overdiagnosis, this roughly implies that,
on average, screening brings forward diagnosis by about 2 years.
The mean sojourn time in mammography screening has been
estimated as about 4 years in the age group 50–69 (Chen et al,
1997). An average lead time of about 2 years would therefore not
be an unreasonable estimate. Therefore, the magnitude of the
prevalence peak in Copenhagen and Fyn can be interpreted as an
indication of lead time and thus of no overdiagnosis in the
prevalence round.
In both regions, about 18% of the participants in the second
invitation round were newcomers. The sensitivity for detection
of invasive cancers was calculated as screen detected cancers/
(screen detected cancers + interval cancers). During the first
invitation round, sensitivity was 87% in Copenhagen and 80%
in Fyn. In Copenhagen, 11% of the invasive cases detected during
the first invitation round had the final diagnosis made during
the second invitation round, and in the present analysis
were counted as incident cases during the second round. In
Copenhagen, the participation rate declined from 71% during the
first invitation round, to 65 and 63% in the subsequent rounds,
tending to lower the observed incidence during the later rounds. In
Fyn, 88% participated in the first round. Thus, several factors
tended to push the incidence upwards during the second and
third invitation rounds, and only one factor operated in the
opposite direction. This incidence was similar to that expected
without screening and therefore seems a good indicator of no
overdiagnosis.
In both Copenhagen and Fyn, throughout the programme about
11% of the screen-detected cases were DCIS. We tabulated the
combined incidence of invasive breast cancer and screen-detected
DCIS cases, but the pattern was almost identical with that for
invasive cancer only (data not shown).
In Frederiksberg, the increase in the incidence continued
after the first invitation round. This small municipality is located
within Copenhagen, and the incidence prior to screening was
similar in the two areas. It should be noted that the second
invitation round was postponed for 4 months when Frederiksberg
was incorporated into the Copenhagen programme. The detection
rate of invasive cancer and DCIS was 9.5 per 1000 screened in the
first invitation round in Frederiksberg compared with 11.9 per
1000 screened in Copenhagen. In the second invitation round,
however, the detection rate in Frederiksberg was 8.2 per 1000
screened, whereas it was 6.3 per 1000 in Copenhagen. The two
municipalities thus had similar average detection rates for the first
two invitation rounds: (9.5+8.2)/2¼8.9 and (11.9+6.3)/2¼9.1,
respectively.
Our study showed that in Copenhagen and Fyn, incidence
during the second and third invitation rounds was fairly similar to
that expected in the absence of the screening. It is therefore
reasonable to conclude that screening did not lead to over-
diagnosis of breast cancer. The pattern was different in the small
municipality of Frederiksberg, where the continued high incidence
during the second invitation round was probably partly because of
a low sensitivity during the first round.
Overdiagnosis is an important potential disadvantage of screen-
ing, which is difficult to monitor in gradually introduced or
opportunistic screening. Our results indicate that well-organised
mammography screening can operate without overdiagnosis of
breast cancer.
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